Effect of Low-Dose Pioglitazone in Patients With Nonalcoholic Steatohepatitis (NASH)
Latest Information Update: 01 Apr 2024
At a glance
- Drugs Pioglitazone (Primary)
- Indications Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 16 Feb 2023 Planned End Date changed from 29 Feb 2024 to 31 Aug 2027.
- 16 Feb 2023 Planned primary completion date changed from 29 Feb 2024 to 31 Aug 2027.
- 15 Sep 2022 Planned number of patients changed from 138 to 166.